Trials / Completed
CompletedNCT01090037
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 892 (actual)
- Sponsor
- Toray Industries, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: * To confirm the superiority of TRK-100STP over placebo * To determine the recommended therapeutic dose in the 2 doses of TRK-100STP * To assess the safety of TRK-100STP
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRK-100STP high dose | |
| DRUG | TRK-100STP low dose | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2014-08-01
- Completion
- 2015-01-01
- First posted
- 2010-03-19
- Last updated
- 2015-02-04
Locations
7 sites across 7 countries: China, Hong Kong, Japan, Malaysia, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT01090037. Inclusion in this directory is not an endorsement.